seekingalpha article on venous ulcers, page-3

"We think ReCell compares well with these products on a cost and effectiveness standpoint, and that confirmation of results seen to date in venous leg ulcer could potentially lead to $50-100 million in peak revenues. In our previous article on Avita focusing on burns and scalds, we suggested that ReCell could have a $200 million peak revenue opportunity in that indication. Approvals in these indications would clearly be an enormous leap forward for this $40 million market capitalization company."

Very nice. even if only make half the prodiction. Say $100mil a year. That should still give us a market cap around $400mil or 10 times the value of where we are at now.